S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Intellia Therapeutics Stock Forecast, Price & News

-8.92 (-8.11%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
979,055 shs
Average Volume
1.48 million shs
Market Capitalization
$7.42 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Intellia Therapeutics logo

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.


Investing in Genomics Stocks
December 2, 2021 |  fool.com
Intellia Therapeutics Continues Downtick
October 8, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$57.99 million
Book Value
$15.06 per share


Net Income
$-134.23 million
Net Margins
Pretax Margin




Free Float
Market Cap
$7.42 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.32 out of 5 stars

Medical Sector

281st out of 1,388 stocks

Diagnostic Substances Industry

3rd out of 25 stocks

Analyst Opinion: 4.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

Is Intellia Therapeutics a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics
or view top-rated stocks.

How has Intellia Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NTLA stock has increased by 694.3% and is now trading at $101.03.
View which stocks have been most impacted by COVID-19

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Intellia Therapeutics

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.97) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.85) by $0.12. The firm had revenue of $7.20 million for the quarter, compared to the consensus estimate of $8.66 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 34.22% and a negative net margin of 854.10%. The business's revenue for the quarter was down 67.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.47) EPS.
View Intellia Therapeutics' earnings history

What price target have analysts set for NTLA?

18 equities research analysts have issued 1 year target prices for Intellia Therapeutics' shares. Their forecasts range from $52.00 to $252.00. On average, they expect Intellia Therapeutics' stock price to reach $146.28 in the next year. This suggests a possible upside of 44.8% from the stock's current price.
View analysts' price targets for Intellia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.53%), Sumitomo Mitsui Trust Holdings Inc. (3.27%), Nikko Asset Management Americas Inc. (3.27%), Viking Global Investors LP (1.74%), Alliancebernstein L.P. (1.68%) and Geode Capital Management LLC (1.63%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Caption Management LLC, Two Sigma Advisers LP, Jennison Associates LLC, Temasek Holdings Private Ltd, Jane Street Group LLC, and Chevy Chase Trust Holdings Inc.. Company insiders that have sold Intellia Therapeutics company stock in the last year include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, Jose E Rivera, Laura Sepp-Lorenzino, and Perry A Karsen.
View insider buying and selling activity for Intellia Therapeutics
or view top insider-selling stocks.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., Morgan Stanley, Victory Capital Management Inc., Viking Global Investors LP, Wellington Management Group LLP, Two Sigma Investments LP, and Coatue Management LLC.
View insider buying and selling activity for Intellia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $101.03.

How much money does Intellia Therapeutics make?

Intellia Therapeutics has a market capitalization of $7.42 billion and generates $57.99 million in revenue each year. The company earns $-134.23 million in net income (profit) each year or ($3.36) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

Intellia Therapeutics employs 312 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

Where are Intellia Therapeutics' headquarters?

Intellia Therapeutics is headquartered at 40 Erie Street Suite 130, Cambridge MA, 02139.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at (857) 285-6200 or via email at [email protected].

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.